BIOCYTOGEN
6.5.2024 16:01:35 CEST | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotechnology company focused on the discovery of novel antibody-based therapeutics, today announced a TCR-mimic antibody evaluation and potential licensing agreement with BioCopy AG (“BioCopy”), a research-based biotechnology company headquartered in Basel, Switzerland.
The agreement grants BioCopy access to fully human TCR-mimic antibodies targeting an intracellular antigen generated by Biocytogen’s proprietary RenTCR-mimicTM mice. BioCopy will conduct an evaluation and retain the option to license these antibodies for the development of novel cancer therapies.
“We are glad to provide BioCopy with our TCR-mimic antibodies,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Our in vivo matured TCR-mimic antibodies demonstrated favorable affinity and excellent specificity. Combined with BioCopy’s expertise in TCR-mimic antibody screening and engager development, we are optimistic that our collaboration will generate novel drugs that benefit cancer patients.”
BioCopy will use Biocytogen’s TCR-mimic antibodies and test them against promising intracellular tumor associated antigens. Here, BioCopy will use its automated end-to-end platform for the optimization of multispecific biotherapeutics to further develop these TCR-mimic antibodies into next-generation oncological drugs.
About Biocytogen’s TCR-mimic Antibody Discovery Platform
Biocytogen’s TCR-mimic platform focuses on the discovery of fully human antibodies to intracellular targets that are presented on the cell surface by MHC class I molecules. Leveraging proprietary RenTCR-mimicTM (HLA/RenMab) mice and specialized immunization protocols, Biocytogen’s platform is designed to generate TCR-mimic antibodies that are highly specific for peptide/HLA complexes and not HLA itself. Using a high-throughput antibody screening platform, Biocytogen swiftly identifies TCR-mimic antibodies with higher specificity and affinity than endogenous TCRs derived from patients to overcome tumor immune escape. Currently, antibody hits for multiple intracellular targets, including TAAs, cancer-testis antigens, mutated protein antigens, and viral protein antigens, are being evaluated in vivo and in vitro. Fully human antibody sequences obtained from the TCR-mimic platform can empower the development of T cell engagers, bispecific/multispecific antibodies, and CAR-T therapies.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of December 31, 2023, 103 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 47 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), the USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
About BioCopy
BioCopy is a multinational company headquartered in Switzerland with a state-of-the-art R&D facility in Germany. The company focuses on biotherapeutic drug discovery and development using their end-to-end automated, AI-powered platform. BioCopy is convinced that cancer can be cured with ingenuity and AI, supported by the extraordinary power of our body’s own immune system. With the company’s unique platform, BioCopy is working continuously to develop next-generation biotherapeutic drug candidates with unprecedented efficacy and safety, transforming today’s pharmaceutical industries.
Website: www.biocopy.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240506586492/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rubrik Security Cloud Launches on the AWS European Sovereign Cloud8.7.2026 09:00:00 CEST | Press release
The launch will allow highly regulated European Union organisations to meet strict EU data residency requirements Rubrik, the Security and AI Operations Company, today announced the availability of Rubrik Security Cloud on the AWS European Sovereign Cloud, providing the European Union (EU) public sector and highly regulated private organisations with a cloud-native path for sovereign cyber resilience. Organisations increasingly require resilience measures that are sovereign, not just contractually compliant. Rubrik Security Cloud on the AWS European Sovereign Cloud meets this demand. It will allow highly regulated industries, such as banking, utilities, healthcare, and government, to leverage the full power of AWS, while meeting stringent data residency requirements within the European Union (EU). Advanced security features on a fully featured, independently operated sovereign cloud The AWS European Sovereign Cloud is a fully featured, independently operated sovereign cloud backed by s
Wolters Kluwer Brings Libra AI Workflows Into One for Italian Legal Professionals8.7.2026 09:00:00 CEST | Press release
Building on Libra by Wolters Kluwer’s early leadership, strong market momentum and advanced AI innovation in Italy, its capabilities are now directly available in One via the Libra add-in. Wolters Kluwer Legal & Regulatory today announced the integration of Libra by Wolters Kluwer AI workflows in One, its leading legal research platform in Italy. This step further reinforces the strong commercial success and rapid market adoption of the Libra legal AI workspace in the country. With the integration generative AI features are directly available in the research workflow of legal professionals allowing a seamless experience without switching between tools. The integration follows the launch of the Libra legal AI workspace in Italy in February, setting a new benchmark for AI-enabled legal research by combining advanced AI capabilities with authoritative and trusted legal content from One and supporting lawyers across their full workflow, from research to analysis and document drafting. With
Flix and Klarna Expand Partnership to Give Millions of Travelers Across the U.S. and Europe More Ways to Pay8.7.2026 09:00:00 CEST | Press release
Flix and Klarna, the global digital bank and flexible payments provider, today announced an expanded partnership that brings more flexible payment options to millions of travelers across its platforms. Beginning today, Klarna will be available in 21 Flix markets, adding the UK, Germany, Italy, France, Poland, Switzerland, Austria, and Spain, among others, to its existing presence in the U.S. and Sweden. With Klarna now embedded directly into the Flix booking flow, passengers have three new ways to pay: in full at the time of booking, in interest-free installments, or through longer-term financing for larger purchases. For cross-border journeys, Klarna removes foreign exchange fees, letting travelers pay in their local currency with no hidden conversion costs. Klarna users will also receive exclusive deals when booking through Flix platforms. "Travel is one of the biggest spending categories in people's lives, yet flexibility at checkout has lagged behind,” said David Sykes, Chief Comme
Record Launches "Record Amanah" Sharia-Compliant Investment Platform8.7.2026 09:00:00 CEST | Press release
Record Asset Management GmbH (RAM), subsidiary of London-listed Record plc (Record Financial Group), is pleased to announce the launch of Record Amanah, its dedicated platform for Sharia-compliant investment solutions. RAM is the European asset management arm of Record Financial Group, the London-listed specialist investment group managing USD 115 billion of assets on behalf of institutional clients worldwide. Record's client base comprises pension funds, foundations, sovereign institutions and other asset managers, with whom the Group has built long-standing relationships through its focus on bespoke investment and risk management solutions. Headquartered in London, Record has offices in Hamburg, Zurich, Zug, New York, and Hong Kong. The launch follows a series of successful Sharia-compliant transactions completed by Record, most recently for a client in Brunei, and reflects growing demand from institutional investors seeking investment opportunities that combine attractive risk-adjus
Axelspace’s Seven GRUS-3 Earth Observation Microsatellites Successfully Launched and First Signals Received8.7.2026 07:00:00 CEST | Press release
Axelspace Corporation (“Axelspace”), a leading developer and operator of microsatellites dedicated to realizing its vision of “Space within Your Reach,” announced that the seven GRUS-3 next-generation Earth observation microsatellites were successfully launched and that the first radio signals were successfully received. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707291751/en/ The successful launch of Falcon 9 ©SpaceX GRUS-3 was integrated via Exolaunch and launched aboard a SpaceX Falcon 9 rocket from Vandenberg Space Force Base in California, USA, on July 7, 2026 at 07:12 (UTC) during the Transporter-17 rideshare mission. The satellites were successfully put into their intended orbit. Axelspace received the first radio signals from all the seven satellites in orbit. The satellites are currently operating normally. Axelspace is working toward completing the critical operation of the GRUS-3 microsatellite to ensure pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom